Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older~* Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease~* Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC~* Existence of at least 1 measurable lesion by RECIST v1.1~* Adequate hematological, renal and liver function~* Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1~* Life expectancy longer than 6 months~Exclusion Criteria:~* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature~* Any unresolved toxicities from prior systemic therapy~* Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations~* Previous dosing with vascular endothelial growth factor (VEGF) inhibitor~* Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy~* Use of prohibited concomitant medication~* Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection~* Fertile men or women of childbearing potential not using adequate contraception.~Other inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FKB238 / paclitaxel / carboplatin (Type: EXPERIMENTAL): Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
- Avastin / paclitaxel / carboplatin (Type: ACTIVE_COMPARATOR): Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).